Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,269 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammatory Bowel Diseases Clear all
Not listed Phase 1 Interventional

Pilot Study of a New Medical Food in the Management of Ulcerative Colitis

NCT06116643
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Soluble protein hydrolysate (SPHi)
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 21, 2026, 2:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Healthy Endoscopy Study

NCT04369963
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Functional Gastrointestinal Disorders
Interventions
Esophagogastroduodenoscopy and Colonoscopy with Biopsies
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years to 25 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 1 Interventional

Pediatric MSC-AFP Sub-study for Crohn's Fistula

NCT03449069
View directory record Official record
Conditions
Fistula in Ano, Crohn Disease
Interventions
MSC-AFP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

NCT03009396
View directory record Official record
Conditions
Crohn Disease
Interventions
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 76 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
San Carlos, California • Marietta, Georgia • Topeka, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 21, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional Results available

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

NCT01009281
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
AIN457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Bristol, Connecticut • Great Neck, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dietary Treatment of Crohn's Disease

NCT00343642
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
Active fructo-oligosaccharide, Placebo fructo-oligosaccharide, Diet
Drug · Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Macon, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

NCT00587041
View directory record Official record
Conditions
Nephrolithiasis, Hyperoxaluria, Crohn's Disease
Interventions
Oxadrop, Agri-King Synbiotic (AKSB), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

NCT01284062
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Anrukinzumab, placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Early Phase 1 Interventional

Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

NCT02925351
View directory record Official record
Conditions
Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Takayasu Arteritis
Interventions
Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 21, 2026, 2:48 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of the Enhanced Recovery After Surgery System for Colorectal Surgery

NCT02997293
View directory record Official record
Conditions
ColoRectal Cancer and Inflammatory Bowel Disease
Interventions
Enhanced Recovery protocol
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

NCT03395184
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-06651600 Placebo, PF-06651600, Placebo PF-06700841, PF-06700841
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
57
States / cities
Dothan, Alabama • Beverly Hills, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 21, 2026, 2:48 PM EDT
Recruiting Not applicable Interventional

Functional Outcomes in Ulcerative Colitis Patients With Ileal Pouch Anal Anastomosis Treated With High Intensity Focused Electromagnetic Stimulation

NCT07034443
View directory record Official record
Conditions
Fecal Incontinence
Interventions
High Intensity Focused Electromagnetic Stimulation
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 21, 2026, 2:48 PM EDT
Recruiting Phase 2 Interventional

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099
View directory record Official record
Conditions
Crohn Disease
Interventions
LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 21, 2026, 2:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cell Transplantation in Crohn's Disease

NCT04224558
View directory record Official record
Conditions
Crohn Disease
Interventions
Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
Drug · Procedure · Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years to 28 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 21, 2026, 2:48 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

NCT04590508
View directory record Official record
Conditions
Crohn Disease
Interventions
Xanthohumol, Placebo
Drug · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 21, 2026, 2:48 PM EDT
Terminated Phase 4 Interventional Results available

Corticosteroids With Vedolizumab in Crohn's Disease

NCT02324699
View directory record Official record
Conditions
Crohn's Disease
Interventions
Prednisone, Placebo, Vedolizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 21, 2026, 2:48 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Upadacitinib (ABT-494), Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
147
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 21, 2026, 2:48 PM EDT
Not listed Not applicable Interventional

Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis

NCT05662059
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RAVANS, RAVANS-sham
Device
Lead sponsor
Cala Health, Inc.
Industry
Eligibility
10 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Dothan, Alabama • Sun City, Arizona • Lancaster, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 21, 2026, 2:48 PM EDT
Terminated Not applicable Interventional Results available

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

NCT01156480
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
hydrocortisone, placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
0 Days to 6 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

B0151005 Open-Label Extension Study

NCT01345318
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-04236921
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
62
States / cities
Scottsdale, Arizona • Tucson, Arizona • Lakewood, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 3 Interventional

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

NCT00338650
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2007 · Synced Sep 21, 2026, 2:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Remote Physiologic Monitoring to Detect Inflammatory Bowel Disease (IBD) Flares: A Feasibility Study

NCT04333810
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Whoop strap 3.0
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 21, 2026, 2:48 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion

NCT01949896
View directory record Official record
Conditions
Transfusions
Interventions
NPO, Control group: continue feedings
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
3 Days to 6 Months
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 21, 2026, 2:48 PM EDT